Gulam A. Manji

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Medicine, Oncology, Pharmacology +11

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Michael S. Lee, Baek‐Yeol Ryoo, Chih‐Hung Hsu et al. · The Lancet Oncology · 2020 · 567 citations

Medicine, Oncology, Pharmacology +14

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

PYPAF7, a Novel PYRIN-containing Apaf1-like Protein That Regulates Activation of NF-κB and Caspase-1-dependent Cytokine Processing

Lin Wang, Gulam A. Manji, Jill M. Grenier et al. · Journal of Biological Chemistry · 2002 · 370 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF‐κB and caspase‐1

Jill M. Grenier, Lin Wang, Gulam A. Manji et al. · FEBS Letters · 2002 · 305 citations

Life Sciences, Immunology, Molecular Biology +10